These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 34899612

  • 1. Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.
    Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F, Cheng R.
    Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
    [Abstract] [Full Text] [Related]

  • 2. Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study.
    Xie L, Li Y, Zhang J, Guo S, Chen Q, Ma H, Jiang W.
    Eur J Pediatr; 2024 Oct; 183(10):4531-4539. PubMed ID: 39158594
    [Abstract] [Full Text] [Related]

  • 3. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C.
    Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of PEGylated recombinant human growth hormone in treating Chinese children with growth hormone deficiency: a 5-year retrospective study.
    Hou L, Lin S, Liu Z, Zhang L, Ou H, Huang S, Dai H, Meng Z, Liang L.
    J Pediatr Endocrinol Metab; 2024 Oct 28; 37(10):892-899. PubMed ID: 39190198
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L, Luo XP, Du ML, Ma HM, Gong CX, Li YC, Shen SX, Zhao ZH, Liang L, Dong GP, Yan CY, Du HW.
    Zhonghua Er Ke Za Zhi; 2009 Jan 28; 47(1):48-52. PubMed ID: 19573383
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency.
    Du H, Wu D, Yi P, Bai X, Luo Y, Yang H, Chen S, Pan H, Zhu H.
    J Pediatr Endocrinol Metab; 2022 Apr 26; 35(4):511-517. PubMed ID: 35245011
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetic/pharmacodynamic analysis of PEG-rhGH enhances confidence in exploring dosing schemes with longer intervals.
    Cheng R, Zhao Q, Zhong G, Xu J, Zheng Z, Xi L, Zhang M, Ni J, Hu P, Luo F, Lu W.
    Eur J Pharm Sci; 2022 Dec 01; 179():106304. PubMed ID: 36209987
    [Abstract] [Full Text] [Related]

  • 8. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
    Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X.
    Front Endocrinol (Lausanne); 2022 Dec 01; 13():922304. PubMed ID: 36034448
    [Abstract] [Full Text] [Related]

  • 9. Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study.
    Hou L, Huang K, Gong C, Luo F, Wei H, Liang L, Du H, Zhang J, Zhong Y, Chen R, Chen X, Pan J, Jin X, Zeng T, Liao W, Liu D, Lan D, Zhu S, Dong Z, Ma H, Yang Y, Xiong F, Lu P, Cheng S, Gu X, Jin R, Liu Y, Wu J, Xu X, Chen L, Dong Q, Pan H, Su Z, Liu L, Luo X, Ni S, Chen Z, Hu Y, Wang C, Liu J, Liu L, Lu B, Wang X, Wang Y, Yang F, Zhang M, Cao L, Liu G, Yao H, Zhan Y, Dai M, Li G, Li L, Liu Y, Wang K, Xiao Y, Zhang X, Dong J, Gu Z, Ying L, Huang F, Liu Y, Liu Z, Ye J, Zhao D, Hu X, Jiang Z, Ye K, Zhu H, Chen S, Chen X, Wan N, Xu Z, Yin Q, Zhang H, Huang X, Yin J, Zhang H, Li P, Yin P, Fu J, Luo X.
    J Clin Endocrinol Metab; 2023 Jul 14; 108(8):2078-2086. PubMed ID: 36669772
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
    Hou L, Liang Y, Wu W, Lin HH, Luo XP, Ying YQ.
    Growth Horm IGF Res; 2020 Jul 14; 53-54():101331. PubMed ID: 32777706
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
    Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS.
    J Clin Endocrinol Metab; 2022 Jun 16; 107(7):e2717-e2728. PubMed ID: 35405011
    [Abstract] [Full Text] [Related]

  • 12. Long-acting PEGylated growth hormone in children with idiopathic short stature.
    Luo X, Zhao S, Yang Y, Dong G, Chen L, Li P, Luo F, Gong C, Xu Z, Xu X, Gong H, Du H, Hou L, Zhong Y, Shi Q, Chen X, Chen X, Xu L, Cheng R, Su C, Ma Y, Xu L, Zhang L, Lu H.
    Eur J Endocrinol; 2022 Nov 01; 187(5):709-718. PubMed ID: 36130048
    [Abstract] [Full Text] [Related]

  • 13. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L, Chen ZH, Liu D, Cheng YG, Luo XP.
    Drug Des Devel Ther; 2016 Nov 01; 10():13-21. PubMed ID: 26719670
    [Abstract] [Full Text] [Related]

  • 14. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
    Liang L, Zou CC, Li Y, Wang CL, Jiang YJ, Dong GP, Fu JF, Wang XM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 01; 44(9):657-61. PubMed ID: 17217656
    [Abstract] [Full Text] [Related]

  • 15. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ.
    Horm Res Paediatr; 2020 Sep 01; 93(3):154-163. PubMed ID: 32814319
    [Abstract] [Full Text] [Related]

  • 16. Post hoc subgroup analysis of Asian children with paediatric GHD from the global phase 3 efficacy and safety study of once-weekly somatrogon vs. once-daily somatropin.
    Gomez R, Khadilkar V, Shembalkar J, Chu DM, Ko CW, Wajnrajch MP, Wang R.
    J Pediatr Endocrinol Metab; 2024 Jun 25; 37(6):525-531. PubMed ID: 38717038
    [Abstract] [Full Text] [Related]

  • 17. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.
    Soliman AT, Elawwa A, Itani M, Jour C, De Sanctis V.
    Acta Biomed; 2019 Sep 23; 90(8-S):43-51. PubMed ID: 31544806
    [Abstract] [Full Text] [Related]

  • 18. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
    Sävendahl L, Battelino T, Brod M, Højby Rasmussen M, Horikawa R, Juul RV, Saenger P, REAL 3 study group.
    J Clin Endocrinol Metab; 2020 Apr 01; 105(4):e1847-61. PubMed ID: 31917835
    [Abstract] [Full Text] [Related]

  • 19. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study.
    Jiang Z, Chen X, Dong G, Lou Y, Zhang J, Cheng X, Pan J, Liao W, Wu J, Huang X, Jin X, Liu D, Zeng T, Zhu S, Dong Q, Luo X, Lan D, Cao L, Zhang X, Liu J, Dai M, Zhang M, Liu L, Dong J, Zhao D, Ni S, Fu J.
    Front Pharmacol; 2022 Apr 01; 13():955809. PubMed ID: 36034802
    [Abstract] [Full Text] [Related]

  • 20. Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.
    Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F, Cheng R.
    Front Endocrinol (Lausanne); 2021 Apr 01; 12():830469. PubMed ID: 35027911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.